<DOC>
	<DOC>NCT02458677</DOC>
	<brief_summary>This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 40 healthy subjects.</brief_summary>
	<brief_title>Single Ascending Dose Study of PRX003 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Healthy subjects Body mass index (BMI) between 1832 kg/m2 with a minimum weight of 45 kg Female subjects must be surgically sterile or postmenopausal or if of childbearing potential must use contraception Male subjects and their partners of childbearing potential must use contraception Positive test for drug of abuse Past or current history of alcohol abuse Positive for TB, hepatitis B, hepatitis C or HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>